Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity?

被引:102
作者
Licht, RW [1 ]
Qvitzau, S
Allerup, P
Bech, P
机构
[1] Aarhus Univ, Hosp Psychiat, Mood Disorders Res Unit, DK-8240 Risskov, Denmark
[2] Pfizer Denmark, Copenhagen, Denmark
[3] Aarhus Univ, Copenhagen, Denmark
[4] Frederiksborg Cent Cty Hosp, Psychiat Res Unit, Hillerod, Denmark
关键词
major depressive disorder; acute therapy; sertraline; rating scales; validity; antidepressant drug trials;
D O I
10.1111/j.1600-0447.2004.00440.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Evaluation of antidepressant drug efficacy requires adequate rating scales for measuring the severity of depression. However, to measure the illness severity by such a total score, the scale needs to fulfil criteria of unidimensionality. On this background, we aimed at comparing the unidimensionality of the Bech-Rafaelsen Melancholia Scale (MES) and the 17-item Hamilton Depression Rating Scale (HAM-D-17). Method: A total of 1629 patients aged between 18 and 65 years with a major depressive episode were treated openly with sertraline at a fixed oral dose of 50 mg daily during 4 weeks. The HAM-D-17 and the MES were applied at baseline and at weeks 2 and 4. Unidimensionality was tested with Mokken and Rasch analysis. Results: Unidimensionality of the HAM-D-17 could not be confirmed. However, the 6-item Hamilton Depression Subscale (HAM-D-6), was accepted by the Rasch analysis both at baseline and after 2 and 4 weeks of therapy. For the MES (as well as for the HAM-D-6), a Loevinger coefficient of homogeneity above 0.40 (suggesting acceptance) was found at week 4. Conclusion: The HAM-D-6 and the MES did fulfil criteria for unidimensionality while the HAM-D-17 did not. Therefore, the extended use of the HAM-D-17 in drug trials may be questioned.
引用
收藏
页码:144 / 149
页数:6
相关论文
共 31 条
  • [1] ALLERUP P, 1986, STAT ANAL RATING SCA
  • [2] Allerup P, 1997, APPL LATENT TRAIT LA, P50
  • [3] Allerup P, 1994, INT ENCY ED, V8, P4902
  • [4] ANDERSON IM, 1986, PSYCHOPHARMACOLOGY, V89, P131
  • [5] [Anonymous], 1994, DIAGN STAT MAN MENT
  • [6] Bech P, 1999, WPA SER EVID EXPER P, V1, P89
  • [7] The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure
    Bech, P
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2002, 106 (04) : 252 - 264
  • [8] The major depression rating scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials
    Bech, P
    Stage, KB
    Nair, NPV
    Larsen, JK
    KraghSorensen, P
    Gjerris, A
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1997, 42 (01) : 39 - 48
  • [9] Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression
    Bech, P
    Cialdella, P
    Haugh, MC
    Birkett, MA
    Hours, A
    Boissel, JP
    Tollefson, GD
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2000, 176 : 421 - 428
  • [10] QUANTITATIVE RATING OF DEPRESSIVE STATES
    BECH, P
    GRAM, LF
    DEIN, E
    JACOBSEN, O
    VITGER, J
    BOLWIG, TG
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1975, 51 (03) : 161 - 170